title: Interferon-alpha and synthetic peptide malaria sporozoite vaccine in non-immune adults: antibody response after 40 weeks.
abstract: Adults with no known immunity to sporozoites received, i.m., at weeks 0 and 8 two single 200 micrograms doses of a peptide Plasmodium falciparum sporozoite vaccine conjugated to tetanus toxoid ((NANP)3-TT) plus placebo (group 1) or interferon-alpha (IFN-alpha) (group 2) and were followed for antibody responses at weeks 4, 12 and 40. Peak antibody responses were observed at week 12. At week 40, a greater than or equal to 4-fold increase in antibody titre to sporozoites in IFA, or to (NANP)50 in ELISA was still detectable in 6 of 12 (50%) volunteers in group 1 and in 16 of 25 (64%) in group 2. Peak antibody titres in IFA and ELISA decreased with a rate of 0.8% and 0.5% per week, respectively.
authors.affiliation: Clinical Research Department, F. Hoffmann-La Roche & Co. Ltd, Basle, Switzerland.
authors.forename: D
authors.initials: D
authors.lastname: Stürchler
authors.forename: G
authors.initials: G
authors.lastname: Zimmer
authors.forename: R
authors.initials: R
authors.lastname: Berger
authors.forename: H
authors.initials: H
authors.lastname: Etlinger
authors.forename: M
authors.initials: M
authors.lastname: Fernex
authors.forename: H
authors.initials: H
authors.lastname: Matile
authors.forename: M
authors.initials: M
authors.lastname: Just
mesh_terms: D000818:Animals; D000913:Antibodies, Protozoan / Q000096:biosynthesis* / Q000302:isolation & purification; D004311:Double-Blind Method; D004797:Enzyme-Linked Immunosorbent Assay; D005455:Fluorescent Antibody Technique; D006801:Humans; D007370:Interferon Type I / Q000494:pharmacology*; D010963:Plasmodium falciparum / Q000276:immunology*; D015800:Protozoan Proteins / Q000276:immunology / Q000494:pharmacology*; D013745:Tetanus Toxoid / Q000276:immunology / Q000494:pharmacology*; D013997:Time Factors; D014614:Vaccines, Synthetic / Q000276:immunology / Q000494:pharmacology*
chemical_list: D000913:Antibodies, Protozoan; D007370:Interferon Type I; D015800:Protozoan Proteins; D013745:Tetanus Toxoid; D014614:Vaccines, Synthetic; C065870:Ro 40-2361